Oncogenic transformation of mesenchymal stem cells decreases Nrf2 expression favoring in vivo tumor growth and poorer survival by Funes, JM et al.
Funes et al. Molecular Cancer 2014, 13:20
http://www.molecular-cancer.com/content/13/1/20RESEARCH Open AccessOncogenic transformation of mesenchymal stem
cells decreases Nrf2 expression favoring in vivo
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Salvador Moncada2 and Chris Boshoff1Abstract
Background: The transcription factor Nrf2 is a key regulator of the cellular antioxidant response, and its activation
by chemoprotective agents has been proposed as a potential strategy to prevent cancer. However, activating
mutations in the Nrf2 pathway have been found to promote tumorigenesis in certain models. Therefore, the role of
Nrf2 in cancer remains contentious.
Methods: We employed a well-characterized model of stepwise human mesenchymal stem cell (MSC) transformation
and breast cancer cell lines to investigate oxidative stress and the role of Nrf2 during tumorigenesis. The Nrf2 pathway
was studied by microarray analyses, qRT-PCR, and western-blotting. To assess the contribution of Nrf2 to transformation,
we established tumor xenografts with transformed MSC expressing Nrf2 (n = 6 mice per group). Expression and survival
data for Nrf2 in different cancers were obtained from GEO and TCGA databases. All statistical tests were two-sided.
Results: We found an accumulation of reactive oxygen species during MSC transformation that correlated with the
transcriptional down-regulation of antioxidants and Nrf2-downstream genes. Nrf2 was repressed in transformed MSC
and in breast cancer cells via oncogene-induced activation of the RAS/RAF/ERK pathway. Furthermore, restoration of
Nrf2 function in transformed cells decreased reactive oxygen species and impaired in vivo tumor growth (P = 0.001) by
mechanisms that included sensitization to apoptosis, and a decreased hypoxic/angiogenic response through HIF-1α
destabilization and VEGFA repression. Microarray analyses showed down-regulation of Nrf2 in a panel of human
tumors and, strikingly, low Nrf2 expression correlated with poorer survival in patients with melanoma (P = 0.0341),
kidney (P = 0.0203) and prostate (P = 0.00279) cancers.
Conclusions: Our data indicate that oncogene-induced Nrf2 repression is an adaptive response for certain cancers
to acquire a pro-oxidant state that favors cell survival and in vivo tumor growth.
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An increase in reactive oxygen species (ROS) is a com-
mon biochemical property of cancer cells [1,2]. However,
excess ROS also induce senescence, cell cycle arrest and
apoptosis [3], indicating that redox homeostasis is tightly
regulated in tumor cells. To offset excess ROS cells have* Correspondence: jmfunes@cnio.es
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reproduction in any medium, provided the ordeveloped regulatory mechanisms, including the induc-
tion of antioxidant enzymes and/or the activation of
redox buffering systems such as glutathione. The tran-
scription factor Nrf2 (NFE2L2) plays a crucial role in the
cellular defense against oxidative stress through its abi-
lity to induce the expression of antioxidant and deto-
xification genes [4,5]. Under basal conditions, Nrf2 is
bound to its inhibitor Keap1 and targeted for degra-
dation by the proteasome pathway [6,7]. Upon certain
stress conditions, Nrf2 is released from the inhibitory
complex and translocates to the nucleus where it binds
antioxidant response elements (ARE) in the promotertd. This is an open access article distributed under the terms of the Creative
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http://www.molecular-cancer.com/content/13/1/20regions of its target genes [8,9]. Among these genes are
NAD(P)H:quinone oxidoreductase 1 (NQO1), heme oxy-
genase 1 (HO-1), members of the glutathione S-transferase
(GST) family and genes involved in NADPH generation
and glutathione biosynthesis [5,10-13].
Activation of the Nrf2-ARE pathway has been proposed
as a potential strategy to prevent cancer because of its abi-
lity to suppress genotoxic insults by inducing antioxidants
and detoxifying enzymes [14-16]. In this regard, nrf2-/- mice
are more susceptible to chemically-induced cancer [17-20],
and Nrf2-deficiency has been suggested to favor metastasis
[21]. However, Nrf2 activation has also been proposed to
play a role in cancer evolution [22-26], and induction of
Nrf2 pathway due to genetic variants in Keap1 or Nrf2
might predispose to cancer [27-30]. Therefore, the role of
Nrf2 in cancer is contentious.
Here we employed a previously well-characterized model
of human mesenchymal stem cell (MSC) stepwise trans-
formation [31] to mechanistically investigate changes in
ROS levels during tumorigenesis. We found an accumula-
tion of ROS during MSC transformation that correlated
with the transcriptional down-regulation of antioxidants
and ARE-containing genes. Moreover, Nrf2 expression was
repressed in transformed MSC and breast cancer cells via
activation of RAS/RAF/ERK pathway, and restoration
of Nrf2 levels in transformed MSC induced the cellular
antioxidant response and impaired in vivo tumor growth
through mechanisms involving sensitization to apoptosis
and destabilization of HIF-1α. Microarray comparison
studies showed that expression of Nrf2 is down-regulated
in a panel of human tumors, and lower expression of Nrf2
is associated with a poorer outcome in patients with
melanoma, kidney and prostate cancers. Overall our re-
sults indicate that defects in the cellular antioxidant
capacity contribute to ROS accumulation during trans-
formation, and that oncogene-induced Nrf2 repression
is an adaptive response for certain cancer cells to ac-
quire a pro-oxidant state that favors cell survival and
tumor growth.
Results
In vitro transformation of human MSC leads to an
increase in intracellular ROS that contributes to the
transformed phenotype
To investigate changes in ROS levels during tumorige-
nesis, we employed a previously developed stepwise trans-
formation model of human MSC (Figure 1A) [31]. Briefly,
primary MSC (MSC0) were sequentially infected with
the human telomerase (hTERT) gene (MSC1) and the
oncoproteins E6 and E7 from HPV-16 (MSC3). The
expression of these genes led to cellular immortalization
and to the inactivation of p53 and pRB tumor suppres-
sors. The additional expression of ST antigen from SV40
(MSC4) and oncogenic H-RasV12 (MSC5) has been shownto induce transformation in other human cells [32]. MSC
expressing these five genes acquired full transformed fea-
tures as showed by their ability to induce tumors in nude
mice [31]. Therefore, MSC5 or transformed MSC were
named thereafter tMSC. To determine the production of
ROS during MSC transformation, we measured ROS
levels by flow cytometry after cell staining with MitoSOX
Red, a dye commonly used for the detection of mito-
chondrial free radical superoxide (O2
• −). This staining
led to more than two fold increase in the fluorescence
intensity of tMSC when compared with immortal MSC1
(Figure 1B). To delineate the step during in vitro trans-
formation where increased ROS occur, we compared the
fluorescence intensity of MSC expressing different onco-
gene combinations after staining with CM-H2DCFDA, a
dye that detects different types of ROS including hydrogen
peroxide (H2O2). While immortal MSC1 produced similar
amounts of ROS to MSC3, the additional expression of ST
(MSC4) and H-RasV12 (tMSC) led to a significant increase
in ROS production (Figure 1C). Since increased ROS have
been shown to promote tumor development and progres-
sion, we next investigated whether ROS scavenging by an-
tioxidants affected the viability and the transforming
capabilities of tMSC. Treatment with N-acetyl-L-cysteine
(NAC) or ascorbic acid diminished the accumulation of
ROS in tMSC (Figure 1D). We also found that NAC
compromised the viability of tMSC, but not that of
immortal MSC3 (Figure 1E) or MSC1 (data not shown).
Furthermore, NAC treatment impaired in vitro transfor-
mation of tMSC measured by colony formation in soft
agarose (Figure 1F), suggesting that a certain threshold of
intracellular ROS levels is required to maintain the trans-
formed phenotype of MSC.
Transformation of MSC induces transcriptional down-
regulation of antioxidant genes
To investigate potential mechanisms for increased ROS in
tMSC we exploited gene expression microarray data pre-
viously generated in our laboratory [31]. Gene Set Enrich-
ment Analysis (GSEA) [33] performed with a compilation of
genes that included a previously published list of genes in-
volved in ROS metabolism [34] (Additional file 1: Table S1)
showed an enrichment of ROS-related genes (q < 0.05) in
those cell lines expressing fewer number of onco-
genes, except for the comparison between MSC4 and
tMSC, where no significant enrichment was observed
(q = 0.4252) (Figure 2A, left panel). Many genes in-
volved in the antioxidant response, including Nrf2
(NFE2L2), were found within the group of genes show-
ing most deregulated expression when MSC0 was com-
pared with tMSC (Figure 2A, right panel). Since Nrf2
binds ARE-containing sequences we used a previously
generated list of genes known to contain ARE in their
promoters (a full list in Supplementary Table Three
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Figure 1 Transformation of human MSC leads to an increase in intracellular ROS that contributes to the transformed phenotype.
(A) Schematic diagram of MSC step-wise transformation. Cell lines were named according to the number of oncogenic ‘hits’ introduced by
sequential retroviral transduction. MSC0 are primary MSC, MSC1 are MSC0 expressing hTERT, MSC3 are MSC1 expressing E6 and E7 from HPV-16,
MSC4 are MSC3 expressing ST antigen from SV40, and MSC5 are transformed MSC (tMSC) obtained after expression of H-RasV12 in MSC4.
(B) Intracellular ROS concentration measured by flow cytometry after staining with MitoSOX Red. ROS amounts are presented as the geometrical
mean fluorescence intensity (± SD) from at least three experiments. (C) Intracellular ROS concentration of MSC expressing different oncogenes measured
by flow cytometry after staining with CM-H2DCFDA. ROS amounts are presented as the geometrical mean fluorescence intensity (± SD) from at least
three experiments. (D) ROS production in tMSC measured by CM-H2DCFDA staining after 4 hours treatment with 2.5 mM N-acetyl-L-cysteine (NAC) or
50 μM ascorbic acid (AsA). ROS levels produced by MSC3 are also shown. (E) Cell viability after 6 and 24 hours treatment with 2.5 mM NAC or vehicle
control was addressed by using CellTiter AQueousOne Solution Cell Proliferation Assay (Promega) following the manufacturer’s instructions.
A representation of three different experiments is shown and data were calculated from the average of four replicate wells. Results are shown
as percentage of viable cells referred to control cells (MSC3) treated with vehicle control. (F) Soft agarose transformation assay of untreated
and 2.5 mM NAC treated tMSC. Colonies were photographed at x40 magnification (top) and counted in triplicate wells (bottom) after 12 days
in culture. P values are *P < 0.05, **P < 0.005 and ***P < 0.0005.
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MSC lines. This analysis showed an enrichment of ARE-
containing genes (q < 0.05) in those cell lines expressing
fewer number of oncogenes, except for the comparison
between MSC4 and tMSC that showed no enrichment
(q = 1) (Figure 2B).
We focused on the last steps during MSC transfor-
mation where significant changes in intracellular ROSlevels were found (from MSC3 to MSC4 and tMSC). qRT-
PCR experiments confirmed down-regulation of Nrf2 and
selected antioxidants and ARE-containing genes when
tMSC were compared with MSC3 and MSC4 (Figure 2C).
One of the most powerful antioxidants and a major redox
buffering mechanism in the cell is the glutathione system
(GSH/GSSG). Expression of genes involved in glutathione
biosynthesis such as glutamate-cysteine ligase catalytic
Figure 2 (See legend on next page.)
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Figure 2 Transformation of MSC induces transcriptional down-regulation of antioxidant genes. (A) The enrichment of genes involved in
ROS metabolism was addressed by GSEA using gene expression microarray data from different paired cell lines (q values from different analysis
are shown). The Y-axis plots the enrichment score and the X-axis is the rank of genes within the ROS list from up-regulated to down-regulated.
The barcode below shows the rank position of individual ROS genes within the list. Arrow indicates ROS genes identified as the core-enriched
genes by GSEA when MSC0 was compared with tMSC. Heatmap at the right panel shows relative expression of genes found within this core-enriched
gene region from cell lines MSC0 and tMSC, where multiple probes per gene were averaged. Results were obtained by performing array experiments
in triplicate (columns). Red indicates up-regulation, and blue down-regulation from the mean. Arrowhead indicates Nrf2 (NFE2L2). (B) GSEA shows the
enrichment of ARE-containing genes for different MSC paired lines. (C) Relative mRNA expression of selected genes involved in antioxidant response
measured by qRT-PCR. These genes include Nrf2, NAD(P)H dehydrogenase quinone 1 (NQO1), heme oxygenase 1 (HO-1), glutathione S-transferase M2
(GSTM2), glucose-6-phosphate dehydrogenase (G6PD), catalase (CAT), glutathione peroxidase 7 (GPX7) and peroxiredoxin 5 (PRDX5). (D) Relative mRNA
expression of genes involved in glutathione biosynthesis (GCLC, GCLM, and GSS) and homeostasis (GSR). (E) Levels of intracellular reduced glutathione
(GSH) presented as relative luciferase units per microgram of protein x105. The result shows the average of 2 experiments performed with at least 4
replicates each. P values are *P < 0.05, **P < 0.005 and ***P < 0.0005.
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one synthetase (GSS) fluctuated during the process of
MSC transformation (Figure 2D). We also found dimin-
ished expression of glutathione reductase (GSR, another
Nrf2-down-stream gene) in tMSC, suggesting that ineffi-
cient conversion of oxidized glutathione (GSSG) to its re-
duced form (GSH) occurs in tumor cells (Figure 2D).
Concurring with these results, tMSC showed the lowest
levels of the active (reduced) form of glutathione (GSH),
the form of glutathione able to provide antioxidant power
(Figure 2E). Overall, these data indicate that transformation
of MSC leads to a global transcriptional down-regulation
of the cellular antioxidant program.
Nrf2 is repressed during cellular transformation via
activation of RAS/RAF/ERK pathway
Western-blot experiments confirmed suppression of
Nrf2 expression and its downstream target NQO1 that
correlated with ST- and H-RasV12-induced activation of
ERK and AKT pathways (Figure 3A). To investigate the
mechanism of Nrf2 repression during transformation,
we focused in the last transformation step where the
more pronounced down-regulation of Nrf2 and ARE-
containing genes occurred. We studied the roles of RAS
and some RAS-downstream effectors by expressing con-
stitutive active mutants of H-RAS (H-RasV12), RAF-1
(Raf-CAAX), and AKT (myrAKT) in immortal MSC4. We
found that activation of RAS and RAF, but not AKT, led
to decreased expression of Nrf2 and NQO1 (Figure 3B).
Recent reports showed that Nrf2 expression was de-
creased in certain human breast cancer cells and breast
tumors when compared with normal mammary epithe-
lial cells or normal breast tissue [36,37]. Interestingly, we
found a reduction in Nrf2 and NQO1 expression when
normal human mammary epithelial cells (HMEC) were
transformed using the same oncogenic elements that we
employed to transform MSC (Figure 3C), suggesting that
this mechanism for Nrf2 regulation is not restricted to
adult MSC. Next we used chemical inhibitors to address
whether Nrf2 expression is transcriptionally regulatedvia ERK or PI3K/AKT pathways in the breast cancer cell
lines MDA-MB-231 and MCF-7. While cell survival was
not affected by the concentration of inhibitors used in
this assay (Additional file 2: Figure S1), treatment with
the ERK inhibitor U0126 led to a significant increase in
the transcription of Nrf2 and NQO1 (Figure 3D). How-
ever, inhibition of AKT with GSK690693, or PI3K with
LY294002 and wortmannin did not induce expression
of Nrf2 nor NQO1 (Figure 3D). The effect of these in-
hibitors on ERK and PI3K/AKT pathways is shown in
Figure 3E, where a modest but consistent activation of
the Nrf2 pathway could be detected following only 16
hours treatment with U0126. Overall our data indicate
that the RAS/RAF/ERK pathway mediates Nrf2 repres-
sion in these cancer cells.
Nrf2 activity was found suppressed in tumor cells due
to increased expression of the ubiquitin ligase Cul3 that,
together with Keap1, targets Nrf2 for degradation by the
proteasome [36]. However, expression of Keap1 (which is
wild type in MSC, data not shown) and Cul3 did not
increase in transformed MSC (Additional file 3: Figure S2).
Nrf2 protein stabilization by means of tert-
butylhydroquinone (TBHQ) impairs MSC transformation
To investigate whether Nrf2 down-regulation contributes
to increased ROS, we induced Nrf2 in tMSC by TBHQ, a
chemical that stabilizes Nrf2 protein by impairing its pro-
teasomal degradation [38,39]. Treatment with TBHQ sta-
bilized Nrf2 (Figure 4A), induced antioxidants (Figure 4A
and B) and reduced ROS levels in tMSC (Figure 4C). We
next tested whether ROS scavenging by TBHQ affected
the transforming capabilities of tMSC. TBHQ significantly
impaired the growth of tMSC, but not that of immortal
MSC3 (Figure 4D). Furthermore, treatment with TBHQ
decreased anchorage-independent growth of both tMSC
and tHMEC measured by soft agarose colony formation
(Figure 4E and Additional file 4: Figure S3, respectively).
These results suggest that loss of Nrf2 expression contri-
butes to both accumulation of intracellular ROS, and to
MSC in vitro transformation.
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Figure 3 (See legend on next page.)
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Figure 4 Chemical stabilization of Nrf2 induces antioxidant enzymes, reduces ROS, and impairs MSC transformation. (A) Nuclear and
total cellular extracts of MSC3 and tMSC treated with 10 μM TBHQ or vehicle for 48 hours were analyzed for the expression of Nrf2, NQO1 or G6PD
by immunoblotting. Rabbit monoclonal antibodies were used for Nrf2, and lamin and actin were used as loading controls. (B) qRT-PCR of
Nrf2 and Nrf2-dowstream genes such as HO-1 and NQO1 was performed in tMSC treated for 48 hours with 10 μM TBHQ or vehicle control.
Non-transformed MSC3 were used as a control. (C) Intracellular ROS concentration measured by CM-H2DCFDA staining in tMSC treated with or
without 10 μM TBHQ for 48 hours. MSC3 ROS levels are also shown. ROS amounts are presented as the geometrical mean fluorescence intensity
(± SD) from at least three experiments. (D) Cell viability after treatment with 10 μM TBHQ or vehicle control. A representation of three independent
experiments is shown and data were calculated from the average of four replicate wells. Results are shown as percentage of viable cells referred to
control cells (MSC3) treated with vehicle control. (E) Soft agarose colonies of tMSC treated with vehicle only or with 10 μM TBHQ were photographed
at x40 magnification after 12 days in culture (top) and counted in triplicate wells (bottom). P values are *P < 0.05 and **P < 0.005.
(See figure on previous page.)
Figure 3 Nrf2 is repressed during cellular transformation via activation of RAS/RAF/ERK pathway. (A) Western-blot shows down-regulation
of Nrf2 and downstream target NQO1 during transformation of human MSC. Activation of AKT and ERK pathways, confirmed by increased
phosphorylation of AKT and ERK1/2 proteins, correlates with decreased expression of Nrf2 and NQO1 in tMSC. (B) Expression of constitutive
active mutants H-RasV12 and Raf-CAAX, but not myrAKT, leads to Nrf2 and NQO1 down-regulation in non-transformed MSC4. (C) Immortal
human mammary epithelial cells (HMEC1) were serially transduced with retroviral vectors encoding the genes E6 and E7 from HPV-16
(HMEC3), ST antigen from SV40 (HMEC4), and H-RasV12 (tHMEC). Top panel shows the number of colonies in soft-agarose counted in triplicate
wells after two weeks in culture. ***P < 0.0005 with respect to all. Western-blot at the bottom panel shows Nrf2 and NQO1 repression during
HMEC transformation. (D) qRT-PCR shows that 16 hours treatment with the ERK inhibitor U0126 induces expression of Nrf2 and its downstream gene
NQO1 in MDA-MB-231 and MCF-7 cells. However, treatment with the AKT inhibitor GSK690693 or with the PI3K inhibitors LY294002 and wortmannin
does not induce Nrf2 expression. DMSO served as a control. (E) Western-blots show inactivation of ERK and PI3K/AKT pathways following 16 hours
treatment with inhibitors. Membranes were probed with rabbit polyclonal antibodies for Nrf2, total ERK1/2, phosphorylated ERK1/2 (p-ERK1/2 (Thr202/
Tyr204)), total AKT, phosphorylated AKT (p-AKT (Ser473)), and monoclonal antibodies for NQO1. Actin and Hsp90 were used as a loading control.
P values are *P < 0.05, **P < 0.005 and ***P < 0.0005.
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Figure 5 Restoration of Nrf2 expression in transformed MSC induces an antioxidant response and impairs tumor growth. (A) Relative
mRNA expression of Nrf2 and selected antioxidants measured by qRT-PCR in tMSC over-expressing either empty vector or Nrf2. These genes
include NQO1, GSTM2, glutamate-cysteine ligase modifier and catalytic subunit (GCLM and GCLC respectively), CAT, GPX7, glutathione reductase
(GSR) and glutathione synthetase (GSS). (B) Total cell extracts of tMSC expressing either empty vector or Nrf2 were analyzed for expression of
Nrf2 and its downstream target NQO1 by immunoblotting. Polyclonal antibodies were used for Nrf2 and GAPDH served as a loading control.
(C) Levels of intracellular reduced glutathione (GSH) presented as relative absorbance units per microgram of protein x105. The result shows the
average of 2 experiments performed with at least 4 replicates each. (D) Intracellular ROS levels of tMSC expressing either empty vector or Nrf2,
measured by CM-H2DCFDA staining. ROS amounts are presented as the geometrical mean fluorescence intensity (± SD) from at least three
experiments. (E) Growth rate of tMSC expressing empty vector or Nrf2 at 5, 24 and 48 hours. The number of viable cells was expressed as relative
absorbance units (R.A.U.). The average of three experiments with at least four replicate wells per cell line and normalized by the amount of protein is
shown. (F) Soft agarose colonies of tMSC over-expressing empty vector or Nrf2 were photographed after 12 days in culture at x40 magnification (top)
and counted in triplicate wells (bottom). (G) Comparison of animal survival between the Nrf2 over-expressing group and empty vector group containing
six mice each (P= 0.001). P values are *P < 0.05 and **P< 0.005.
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Figure 6 Nrf2 sensitizes tMSC to apoptosis and diminishes the in vitro angiogenic response. (A) Apoptosis measured by flow cytometry
after double staining with Annexin-V (FITC) and Propidium Iodide (PI). Left panel shows the percentage of cells in early apoptosis (positive for FITC) and
late apoptosis (positive for FITC and PI) after 24 hours treatment with 5 μM camptothecin. Data show the mean ± S.D. from five independent
experiments. Right panel shows the dot plots of a representative experiment. (B) Western-blot of nuclear and cytoplasmic extracts showing
induction of cleaved PARP protein. Membrane was also probed with mouse monoclonal antibodies against Nrf2. Hsp90 and Lamin served as
loading controls. (C) Caspase 3/7 activity of cells treated likewise. Results are expressed as relative absorbance units normalized by protein amount. Data
show the mean ± S.D. from three independent experiments. (D) Western-blot shows destabilization of HIF-1α protein in Nrf2-over-expressing cells
grown for 48 hours in hypoxia. Membranes were probed with mouse monoclonal antibodies for HIF-1α, Nrf2 and NQO1. HSP90 served as control.
(E) qRT-PCR shows the VEGF-A fold induction in normoxic (21% O2) and 48 hours hypoxic (5% and 1% O2) cells. (F) Effect of hypoxic medium
supernatant from tMSC over-expressing vector or Nrf2 in HUVEC viability. Supernatants from tMSC grown in hypoxia for 48 hours were mixed
with endothelial cell medium at 50% ratio prior to incubation with HUVEC. A representation of three independent experiments shows the
viable cells at 24, 48 and 72 hours as relative absorbance units. Western-blot shows the failure of Nrf2-expressing cells to accumulate HIF-1α
protein in hypoxia (top-right). Increased NQO1 expression indicates activation of Nrf2 pathway. Equal loading of hypoxic tMSC medium
supernatant in HUVEC is shown by coomassie blue staining (bottom-right). P values are *P < 0.05, **P < 0.005 and ***P < 0.0005.
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cellular antioxidant response and impairs in vivo tumor
growth
To validate the observed effect of TBHQ in our model,
we genetically over-expressed Nrf2 in transformed MSC.
tMSC over-expressing Nrf2 exhibited increased transcrip-
tion of ARE-containing genes and antioxidant enzymes
(Figure 5A). Activation of the Nrf2 pathway was con-
firmed by increased expression of Nrf2 and NQO1 pro-
teins (Figure 5B). Furthermore, tMSC over-expressing
Nrf2 showed an increase in the pool of reduced gluta-
thione (Figure 5C) and a decrease in intracellular ROS
(Figure 5D). Next, we investigated how Nrf2-mediated
reduction in ROS levels affected the transformation
capability of tMSC. Over-expression of Nrf2 led to a slight,
but significant reduction in tMSC viability (Figure 5E) and
soft agarose growth (Figure 5F) when compared with
tMSC expressing empty vector. Next we questioned
whether these cells could respond differentially when
they encounter physiological conditions in vivo. Hence
we inoculated tMSC over-expressing Nrf2 or empty
vector into nude mice. While all mice from the empty
vector group showed rapidly growing tumors, only three
out of six mice from the Nrf2 group produced tumors,
and these after a significantly longer latency (P = 0.001)
(Figure 5G).
Nrf2 over-expression sensitizes tMSC to apoptosis and
diminishes the angiogenic response by destabilization of
HIF-1α and VEGF repression
Due to the different responses observed in vitro and
in vivo, we challenged the cells to a variety of stressors in
order to mimic aspects of the in vivo tumor microenviron-
ment. We found that tMSC over-expressing Nrf2 exhibited
more apoptotic cells when compared with control cells
after double staining with Annexin-V (FITC) and Propi-
dium Iodide (Figure 6A). Furthermore, Nrf2 sensitized
cells to apoptosis induced by the DNA-damaging agentcamptothecin (an inhibitor of topoisomerase I) as mea-
sured by staining with Annexin-V (FITC) and Propidium
Iodide (Figure 6A and Additional file 5: Figure S4), by
accumulation of cleaved PARP protein (Figure 6B), and
by increased caspase 3 and 7 activity (Figure 6C). Like-
wise, cells over-expressing Nrf2 showed increased cyto-
toxicity following treatment with the apoptotic inducers
etoposide (a topoisomerase II inhibitor) and the ATP-
competitive kinase inhibitor staurosporine (Additional
file 6: Figure S5).
ROS are implicated in the response to hypoxia through a
mechanism involving stabilization of hypoxia-inducible
factor 1 (HIF-1α) [40]. Interestingly, tMSC over-expressing
Nrf2 were not able to stabilize HIF-1α at 1% O2 concentra-
tion (Figure 6D). Furthermore, the expression of vascular
endothelial growth factor A (VEGFA), an angiogenic
HIF-1α-downstream gene, was significantly reduced in
Nrf2-expressing cells grown at 21% O2 (Figure 6E).
VEGFA production was further decreased when Nrf2-
expressing cells were grown at 5% and 1% O2 concentra-
tions (Figure 6E). Besides, we also found that cells
over-expressing Nrf2 in hypoxic conditions showed
a significant decreased expression of adrenomedullin
(ADM), another HIF-1α-dependent angiogenic and
anti-apoptotic gene [41] (Additional file 7: Figure S6).
Angiogenesis depends on the capacity of endothelial cells
to proliferate and migrate. We next tested whether viability
of human umbilical vein endothelial cells (HUVEC) is
affected by conditioned medium from transformed cells
over-expressing Nrf2. HUVEC cultured with hypoxic con-
ditioned medium from tMSC expressing Nrf2 showed a
significant impairment in viability when compared with
HUVEC treated with hypoxic conditioned medium from
tMSC expressing empty vector (Figure 6F). This result
suggests that loss of Nrf2 expression in tumor cells could
facilitate the proliferation of endothelial cells within the
tumor microenvironment in conditions when oxygen con-
centration becomes limited.
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Figure 7 Decreased Nrf2 expression in certain tumors is associated with poor survival. (A) The analysis of 2548 tumors versus 304 normal
tissues revealed that Nrf2 (NFE2L2) expression is significantly down-regulated in breast, prostate, and kidney (KIRC) tumors (P values in blue),
and significantly up-regulated in colon cancer (P value in red) when compared with normal tissue. However, there are not significant changes
in the expression of NFE2L2 when normal tissue is compared with tumors such as bladder, ovarian, lung adenocarcinoma (LUAD), lung squamous cell
carcinoma (LUSC), lymphoma and melanoma. Data are presented as log-transformed, and normalized by subtracting the mean across all arrays. The
type of tumor and the number of samples analyzed (N) are indicated on the X-axis. These data are taken from TCGA database (https://genome-cancer.
ucsc.edu). (B) Low NFE2L2 expression correlated with poorer survival in patients with melanoma (SKCM, P = 0.0341, N = 172), kidney (KIRC, P = 0.0203,
N = 481) and prostate (PRAD-GSE21034, P = 0.00279, N = 150) cancers. The Kaplan-Meir survival curves for KIRC, survival in days; PRAD-GSE21034,
biochemical recurrence in weeks; and SKCM, survival in days are shown. Samples were categorized as below (lower, black line) or above (higher,
red line) median NFE2L2 expression, and the P values were calculated from the log rank (Mantel Cox) test. The hazard ratio for lower NFE2L2
expression were KIRC: 1.46 (1.06-2.02, 95% conf. lim.), SKCM: 1.62 (1.03-2.57, 95% conf. lim.), PRAD-GSE21034: 2.74 (1.375-5.34, 95% conf. lim.).
(C) In the same expression datasets we find that NFE2L2 expression is significantly positively correlated with GCLC and GCLM in KIRC, with GCLC, GCLM
and NQO1 in PRAD-GSE21034, but with none of these genes in SKCM (as determined using Spearmans rank correlation). The P values are shown for
those genes showing a significant correlation.
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in certain cancers
We next explored whether Nrf2 is differentially expressed
between normal and cancer tissues. Microarray compari-
son studies based on data from the Oncomine database
[42] revealed that the majority of tumors showed low
levels of Nrf2 expression when compared to normal tissue
(Additional file 8: Figure S7). A more comprehensive
microarray analysis based on The Cancer Genome Atlas
(TCGA) database that included 8 of the 10 most common
human malignancies showed that Nrf2 expression was
significantly down-regulated in breast (P = 0.015), pros-
tate (P = 0.00065) and kidney (P = 4.2E-19) tumors, with
only colon cancer showing up-regulated Nrf2 expression
(P = 0.02) when compared to normal tissue (Figure 7A).
We also found a significant down-regulation in the ex-
pression of the Nrf2 downstream genes GCLM, GCLC
and NQO1 in breast, prostate and kidney cancer respect-
ively (Additional file 9: Figure S8), suggesting that Nrf2
protein activity might also be reduced in these tumors. Of
note, analysis of Keap1 expression in these datasets
showed no significant differences between normal and tu-
mors samples, except for lymphoma tumors where Keap1
expression was found up-regulated (P = 4.7E-6) when
compared to normal tissue (Additional file 10: Figure S9).
Next we investigated whether Nrf2 levels are associ-
ated with survival in patients with cancer. Analysis of
available survival datasets obtained from GEO and
TCGA databases showed that lower expression of Nrf2
(NFE2L2) is associated with a significantly poorer out-
come in skin cutaneous melanoma (SKCM) (P = 0.0341)
and in kidney clear cell carcinoma (KIRC) (P = 0.0203)
(Figure 7B). Similarly, low Nrf2 expression was associ-
ated with biochemical recurrence in prostate cancer
(PRAD-GSE21034) (P = 0.00279) [43] (Figure 7B), but
we found no relation positive or negative to prognosis in
any of the other cancers studied (detailed in Additional
file 11: Table S2). The analysis of those cancers where
we found an association between Nrf2 expression andsurvival revealed that the mRNA level of Nrf2 was posi-
tively correlated to its downstream targets in KIRC and
PRAD-GSE21034, but not in SKCM (Figure 7C). These
data suggest that the Nrf2 pathway activity can be dimin-
ished in those tumors exhibiting low Nrf2 expression.
Discussion
Intracellular redox homeostasis is altered in cancer, where
increased levels of ROS favor a pro-oxidant microenviron-
ment [2]. Here we show that MSC accumulate ROS dur-
ing oncogenic transformation, and that transformed MSC
become oxidative stress-dependent, since treatment with
antioxidants decreases ROS levels and impairs their tu-
morigenic potential. Moreover, the increase in ROS coin-
cides with the down-regulation of genes involved in the
cellular antioxidant machinery, including most antioxidant
enzymes, genes implicated in glutathione homeostasis,
and those involved in the biosynthesis of NADPH. It is
believed that a significant amount of the intracellular
ROS is produced by mitochondria. However, ROS can
also be produced by non-mitochondrial sources such as
membrane-bound NADPH oxidases [44]. While the
vast majority of the pro-oxidant enzymes in our list of
ROS genes (including most of the NADPH oxidases) do
not change during MSC transformation (data not
shown), microarray and qRT-PCR analysis showed in-
creased expression of NADPH oxidase 4 (NOX4) and
aldehyde oxidase 1 (AOX1) during MSC transformation
(data not shown). Although the precise contribution of
these enzymes to ROS accumulation is unknown and
needs further investigation, our data overall suggest that
a defective cellular antioxidant system may largely con-
tribute to the high levels of ROS observed during MSC
transformation.
We also found that expression of Nrf2 decreased during
the process of MSC transformation. Although we cannot
rule out the possibility that both ST and oncogenic Ras
may interfere with Nrf2 protein stability, we focused our
attention on the role of H-RasV12 as it induced the most
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indicate that activation of the RAS/RAF/ERK pathway re-
presses Nrf2 expression and contributes to the diminution
of the cellular antioxidant response during MSC trans-
formation. Nrf2 and its downstream target NQO1 were
also suppressed in transformed human mammary epithe-
lial cells, indicating that this mechanism for ROS accumu-
lation is not restricted to adult stem cells. These results
are in concordance with previous reports where ERK
inhibition in the presence of insulin increases ARE-
luciferase activity in HL-1 mouse cardiac cells [45], and
where the RAS/RAF/ERK pathway was proposed to in-
hibit Nrf2 in human neuroblastoma cells with Myc ampli-
fication [46]. Moreover, analysis of previous microarray
studies where investigators have transformed cells in vitro
[47,48] showed that oncogenic transformation leads to
Nrf2 down-regulation in both mouse and human cells
(Additional file 12: Figure S10). However, our results are
in contrast to those from a report by DeNicola et al. [25]
where conditional activation of K-RasG12D in a mouse
model of pancreatic cancer induced the expression of
Nrf2 via the RAF pathway. This divergence could be due
to the different approach employed to express oncogenes,
as H-RasV12 was constitutively expressed in human MSC
and breast epithelial cells, whereas K-RasG12D was condi-
tionally activated in the mouse model. These approaches
might elicit quantitative different levels of Ras activity in
the target cells, resulting in a different regulatory mechan-
ism for Nrf2 expression. However, rather than super-
physiologic expression of Nrf2, we restored Nrf2 levels to
that observed in non-transformed MSC, suggesting that
our model is relevant to transformation of primary human
cells. Other divergences between our work and that from
DeNicola et al. are the different species and tumor models
studied, as well as the different stage during tumor devel-
opment. In this regard, oncogenic Ras might induce differ-
ent biological responses depending on the status of tumor
suppressors such as p53 and/or oncogenes such as Myc.
Here we show that Nrf2-mediated induction of the cel-
lular antioxidant response is an efficient strategy to tackle
in vivo tumor growth in transformed adult stem cells.
Mechanistically, we show that Nrf2 sensitizes transformed
cells to apoptosis, contrasting with previous reports where
Nrf2 was shown to protect from apoptosis and to enhance
drug resistance [49,50]. However, our results are in con-
cordance with previous findings where the presence of
antioxidants was found to improve the cytotoxic effect of
apoptosis-inducing agents [51]. Future studies should
address the effects of Nrf2 on the regulation of pro- and
anti-apoptotic proteins in transformed MSC.
We also provide evidence linking Nrf2 activation with a
reduced angiogenic response under hypoxic conditions. In
agreement with findings that ROS may regulate angiogen-
esis and tumor growth through HIF-1α and VEGF [52],over-expression of Nrf2 in tMSC led to a diminished hyp-
oxic response through destabilization of HIF-1α and re-
duced VEGFA and ADM expression. These data differ
from a report where Nrf2 knockdown by siRNA in human
colon cancer cells inhibited tumor growth and led to a re-
duction in VEGF expression [53]. However, our data sug-
gest that hypoxic conditions could result in a more hostile
microenvironment for cells with higher levels of Nrf2.
All these discrepancies add more complexity to the con-
tentious function of Nrf2 during tumorigenesis. Indeed, it
has been suggested that the role of Nrf2 in cancer is
context-dependent [54]. In this regard, a recent report
based on an urethane-induced multistep mouse model of
lung cancer has proposed that Nrf2 has the dual role of
preventing tumor initiation, but also promoting tumor
progression [55]. However our data reveal a tumor sup-
pressor role for Nrf2 since its down-regulation contributes
to cellular transformation and in vivo tumor growth.
Microarray comparison studies support our experimental
data, indicating that expression of Nrf2 is down-regulated
in many tumors. Moreover, analysis of available survival
datasets obtained from GEO and TCGA databases shows
that increased Nrf2 expression correlates with better
survival in patients with melanoma, kidney and prostate
cancers, further supporting our in vivo findings where
restoration of Nrf2 expression in transformed MSC
improved survival.
Conclusions
Overall our results indicate that defects in the cellular
antioxidant capacity contribute to ROS accumulation
during transformation, and that oncogene-induced Nrf2
repression is an adaptive response for certain cancer
cells that favors in vivo tumor expansion and poorer sur-
vival. We also show that rescue of Nrf2 function in fully
transformed cells is an effective strategy to tackle in vivo
tumor growth, as Nrf2 expression sensitizes transformed
cells to apoptosis and impairs the angiogenic response
through destabilization of HIF-1α.
Methods
Cell culture and generation of stable cell lines
Culture conditions, retrovirus production and gener-
ation of cell lines were previously described [31]. Briefly,
primary human MSC previously isolated from the bone
marrow of a healthy donor (MSC0) according to institu-
tional guidelines were serially transduced with retrovi-
ruses encoding hTERT (MSC1), E6 and E7 from HPV-16
(MSC3), ST antigen from SV40 (MSC4), and H-RasV12
(tMSC). For the generation of tMSC over-expressing Nrf2,
we amplified the Nrf2 gene from human cDNA using the
following primers: forward (5′-GCGGATCCATGATG-
GACTTG-3′) and reverse (5′-ACGCGTCGACCTAGTT
TTTCTTAACATC-3′). Nrf2 was later cloned into pWZL-
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previously introduced with pWZL-blast.
Detection of intracellular ROS
ROS levels were quantified by staining the cells with
MitoSOX Red and CM-H2DCFDA dyes (both from Invi-
trogen, Paisley, UK). After 30 minutes incubation with
the dyes at 5 μM final concentration, cells were collected
and analyzed by flow cytometry using either a FACSCali-
bur instrument (BD Biosciences, San Jose, CA) or a CyAN
flow cytometer (DAKO, Cambridgeshire, UK). Data were
analyzed using either CellQuest V or Summit software.
Cell incubation with MitoSOX was performed in serum-
depleted media.
Transformation assays
Soft agarose colony formation by anchorage-independent
growth and tumor xenografts were previously described
[31]. The animal experiments were conducted in accord-
ance with institutional guidelines under the approved pro-
tocols. For the in vivo tumor growth experiments, Kaplan
Meier survival plots were generated, and from the survival
data a log rank (Mantel-Cox) test was used to demonstrate
significant differences between groups.
Antibodies and reagents
The following antibodies were used for immunoblot-
ting: rabbit polyclonal C-20 (Santa Cruz, CA), mouse
monoclonal (M01) clone 1 F3 (Abnova, Taiwan), and
rabbit monoclonal EP1808Y (Abcam, Cambridge, UK)
for Nrf2; Actin was from Calbiochem/MerckMillipore
(Watford, UK); NQO1 was from Novus Biologicals (Cam-
bridge, UK); G6PD was from Bethyl (Montgomery, TX);
HIF-1α was from BD Biosciences (San Jose, CA); Cleaved
PARP, total AKT, phosphorylated AKT (Ser473) (p-AKT),
total ERK1/2, phosphorylated ERK1/2 (Thr202/Tyr204)
(p-ERK), Cul3, Keap1, HSP90 and Lamin A/C antibodies
were all from Cell Signaling Technology (Danvers, MA);
GAPDH was from Advanced Immunochemical Inc. (Long
Beach, CA); Secondary antibodies were from DAKO.
N-acetyl-L-cysteine, ascorbic acid, tert-butylhydroqui
none, camptothecin, etoposide and staurosporine were
all obtained from Sigma (Dorset, UK).
Cell treatments
Apoptosis was induced by treatment with 5 μM camp-
tothecin for 24 hours, 1 μM etoposide for 48 hours, and
1 μM staurosporine for 3 hours. The percentage of
apoptotic cells was measured by flow cytometry after
double staining with Annexin-V (FITC) and Propidium
Iodide (PI) using the FITC Annexin-V Apoptosis Detec-
tion Kit (BD Pharmingen, San Diego, CA) following the
manufacturer’s instructions. Data were analyzed using
Summit software. Caspase 3/7 activity was quantified byusing Caspase-Glo 3/7 Assay from Promega (Southamp-
ton, UK). Cell viability was addressed by using CellTiter
AQueousOne Solution Cell Proliferation Assay (Promega),
a colorimetric method based on the reduction of a tetrazo-
lium compound by NADPH or NADH produced by de-
hydrogenase enzymes in metabolically active cells. Levels
of reduced glutathione (GSH) were quantified by using
GSH-Glo Glutathione Assay (Promega) following the ma-
nufacturer’s instructions. Nuclear and cytoplasmic protein
fractions were obtained by using NE-PER Nuclear and
Cytoplasmic Extraction Kit (Pierce, Cramlington, UK).
Experiments in hypoxia (1% or 5% oxygen concentration)
were performed as previously described [31].
In the inhibition studies for the RAS-downstream sig-
naling pathways, breast cancer cell lines MDA-MB-231
and MCF-7 were seeded onto 6-well plates and 24 hours
later washed with PBS and subjected to free serum
standard media. 24 hours later the cells were incubated
with free serum standard media containing DMSO (Sigma)
or the following chemicals: ERK kinases inhibitor U0126
(Calbiochem/MerckMillipore, Watford, UK); PI3K inhibi-
tors LY294002 (Merck Biosciences Ltd, Nottingham, UK)
and wortmannin (Cell Signaling Technology, Danvers,
MA); and AKT inhibitor GSK690693 (Symansis, Timaru,
NZ). After 16 hours incubation, RNA was collected and
qRT-PCR was performed. Protein extracts were also col-
lected for western-blot analysis.
Quantitative real-time polymerase chain reaction
(qRT-PCR)
Total RNA was extracted using RNEasy mini kit (Qiagen,
Sussex, UK) and mRNA levels were quantified by qRT-
PCR using Taqman Gene Expression Assays (Applied Bio-
systems, Paisley, UK). SYBR Green Master Mix (Applied
Biosystems) was used with optimized forward (5′-GGA
GTCAACGGATTTGGTCGTA-3′) and reverse (5′-GGC
AACAATATCCACTTTACCAGAGT-3′) primers for GA
PDH (reference gene) at final concentration of 300 nM.
b-Actin (Applied Biosystems) was used as reference gene
for the experiments in hypoxia. All experiments were per-
formed at least by triplicate.
Additional cell lines
Additional MSC lines with activated RAS or RAS-
downstream effectors were generated by infection of
MSC4 with the retroviral vector pBabe-hygro encoding
constitutive active RAS (H-RasV12), the membrane-
targeted RAF-1 (Raf-CAAX), and myristoylated AKT
(myrAKT), all kindly provided by Dr. Pablo Rodriguez-
Viciana (UCL Cancer Institute, London, UK). Immortal
human mammary epithelial cells (HMEC), obtained from
Dr. Rodriguez-Viciana, were cultured in DMEM/F-12
containing 5% horse serum (Life Technologies/Invitrogen,
Paisley, UK) and supplemented with EGF (20 ng/ml)
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cholera toxin (100 ng/ml) and insulin (10 μg/ml), all
from Sigma (Dorset, UK). HMEC expressing different
oncogene combinations were generated after infection
with the same retroviral vectors used for the generation
of MSC lines [31]. Breast cancer cell lines MDA-MB-
231 and MCF-7 were cultured in DMEM containing
10% fetal bovine serum (Life Technologies/Invitrogen).
Human umbilical vein endothelial cells (HUVEC) were
obtained from Promocell (Heidelberg, Germany) and
cultured with Endothelial Cell Growth Medium (Pro-
mocell) according to supplier’s instructions.
Public transcriptome data
The expression level of Nrf2 in many types of cancer was
compared using the Oncomine (https://www.oncomine.
org/resource/login.html) and The Cancer Genome Atlas
(TCGA) (https://genome-cancer.ucsc.edu) databases of
cancer expression data. We downloaded the available ex-
pression data with clinical details for 15 types of cancer
from TCGA (https://tcga-data.nci.nih.gov/tcga) and 3
types of cancer from the NCBI gene expression omnibus
(GEO) (http://www.ncbi.nlm.nih.gov/geo), including 5
separate breast cancer study datasets. In total, for survival
analyses we studied 16 distinct types of cancer. Details of
each dataset, the number of samples with clinical details,
the expression platform, and associated Pubmed IDs for
the GEO datasets are in Additional file 13: Table S3.
Gene expression microarray analysis
Generation of Gene Expression Microarrays (GEM) was
previously described [31] and data were deposited in
ArrayExpress database (accession no. E-MEXP-563). Gene
Set Enrichment Analysis (GSEA) measures the enrich-
ment of a gene set within a GEM experiment. The enrich-
ment score (ES) is a metric of the skew of a gene set
within the rank of genes sorted by their GEM expression
difference. The significance of enrichment (q, or false
discovery rate) is the proportion of true ES >1000 ES
generated from random gene sets (of equal size) (e.g.,
proportion of ESOBSERVED > ESNULL). Leading-edge
genes are the subset that contributes most to the ES.
Statistical analysis
For survival analysis we used the R survival package. To
survey for potential association between gene expression
and survival we categorized samples as below or above
median expression for each gene and then calculated the
log-rank (Mantel Cox) P value comparison between the
groups. For KIRC, SKCM and PRAD-GSE21034 datasets
with significant NFE2L2 log rank tests we also calculated
the hazard ratio using the Cox proportional hazard model.
Elsewhere data were analyzed using Student’s t test,
Spearmans rho or log-rank test as appropriate for theanalysis. Values are given as mean ± SD. All statistical tests
were two-sided, and results were considered statistically sig-
nificant when P < 0.05.Additional files
Additional file 1: Table S1. A list of genes involved in ROS metabolism
was generated based on a published gene list (see Supplementary Table
Four from [34]). Genes included in Sabiosciences (www.sabiosciences.
com) Oxidative Stress Array databases, and other genes known to be
involved in production or scavenging of ROS were also included in this
list. Table shows all the Affymetrix probes for these genes (UNIQID) as well
as the gene names, accession numbers and chromosome localization.
Additional file 2: Figure S1. Percentage of viable MDA-MB-231 cells
(A) and MCF-7 cells (B) after treatment with control DMSO or increasing
concentrations of U0126, LY294002, GSK690693, and wortmannin. Cells
were incubated with the inhibitors for 16 hours in serum free medium
and viability was addressed by using CellTiter AQueousOne Solution Cell
Proliferation Assay (Promega) following the manufacturer’s instructions.
# indicates the concentration of the inhibitors used in the assay.
Additional file 3: Figure S2. Expression of Cul3 and Keap1 does not
significantly increase during the process of MSC transformation. Western-
blot shows Cul3 and Keap1 protein levels. Membrane was also probed
with polyclonal antibodies for Nrf2, and monoclonal antibodies for
NQO1. Actin was used as a loading control.
Additional file 4: Figure S3. Nrf2 stabilization by treatment with TBHQ
reduces tHMEC in vitro transformation. (A) tHMEC treated with 10 μM TBHQ
stabilizes Nrf2 and induces Nrf2-downstream gene NQO1. Membrane was
probed with polyclonal antibodies for Nrf2, and monoclonal antibodies for
NQO1. HSP90 was used as a loading control. (B) Soft agarose colonies counted
in triplicate wells of tHMEC treated with vehicle only or 10 μM TBHQ after 12
days in culture. P value is *P< 0.05.
Additional file 5: Figure S4. Nrf2 sensitizes transformed cells to apoptosis
induced by the DNA-damaging agent camptothecin. (A) Geometrical
mean (Geomean) fluorescence intensity measured by flow cytometry
of transformed cells expressing empty vector or Nrf2 after 24 hours
treatment with either vehicle or 5 μM camptothecin. The data show the
mean ± S.D. from five independent experiments. A representative experiment
is shown in panel (B). P value is *P< 0.05.
Additional file 6: Figure S5. (A) Treatment with the DNA-damaging
agent etoposide (an inhibitor of class II topoisomerase) sensitizes Nrf2-over-
expressing cells to apoptosis measured by increased levels of cleaved PARP
protein. (B) Likewise, cells over-expressing Nrf2 showed increased cytotoxicity
following treatment with the kinase inhibitor staurosporine, as measured by
increased caspase 3 and 7 activity (top panel) and by accumulation of
cleaved PARP protein (bottom panel). Membranes were probed with
polyclonal antibodies for cleaved PARP and Nrf2, and GAPDH served as
loading control. P value is *P < 0.05.
Additional file 7: Figure S6. qRT-PCR experiment showing the relative
mRNA expression of the ADM gene in hypoxic conditions (5% O2 and 1% O2).
To calculate the ADM fold induction relative to normoxia the mRNA levels for
cells grown at 21% O2 were set as 1. P values are *P< 0.05 and ***P< 0.0005.
Additional file 8: Figure S7. Nrf2 was found down-regulated in the
majority of human tumors, as compared to normal tissues (right of vertical
dotted line). For this analysis, 1003 tumors versus 485 normal or benign
samples were included. Data are presented as log-transformed, median
centered per array, and standard deviation normalized to 1 per array.
Only cancers in which statistically significant expression is detected between
normal and matched tumors are presented (P< 0.0001). These data are taken
from Oncomine database (https://www.oncomine.org/resource/login.html).
Additional file 9: Figure S8. Expression of Nrf2 downstream genes
NQO1 and GCLC is significantly down-regulated in kidney and prostate
tumors respectively, whereas GCLM is found down-regulated in lung
adenocarcinoma and breast tumors, but up-regulated in melanoma and
prostate tumors. Data are presented as log-transformed, and normalized
by subtracting the mean across all arrays for each gene. The number of
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those tumors where Nrf2 is down-regulated (in blue) or up-regulated (in
red) are also shown. These data are taken from TCGA database (https://
genome-cancer.ucsc.edu).
Additional file 10: Figure S9. The expression of the Nrf2 inhibitor Keap1
does not significantly change between normal and tumors samples, except
for lymphoma tumors where Keap1 expression was found up-regulated
(P = 4.7E-6) when compared to normal tissue. Data are presented as
log-transformed, and normalized by subtracting the mean across all
arrays for each gene. P values are also shown. These data are taken from
TCGA database (https://genome-cancer.ucsc.edu).
Additional file 11: Table S2. We studied the relationship between
survival and expression of Nrf2 (NFE2L2), GCLM, NQO1 and GCLC in a
wide selection of cancers datasets acquired from GEO and TCGA
databases. Samples were categorized as below or above median
expression for each gene. Table shows the P values calculated from the
log rank (Mantel Cox) test. Data in blue indicates that lower expression is
correlated with poorer survival, and data in red indicates that higher
expression is correlated with poorer survival.
Additional file 12: Figure S10. Heatmaps show down-regulation of
Nrf2 (NFE2L2) and selected antioxidants and Nrf2-downstream genes
following oncogenic transformation of mouse and human cells. Red indicates
up-regulation, and blue down-regulation from the mean. Arrow indicates
Nrf2. (A) Results were obtained from mouse embryonic fibroblast (MEF)
transformed with the adenovirus oncoprotein E1A and H-RasV12 (tMEF).
Microarray data were obtained upon request from Dr. Juan Iovanna [47].
(B) Results were obtained from human primary diploid fibroblasts IMR90
(HF) transformed with five oncogenic hits including hTERT, MEK1 (MEK-ER),
E6 and E7 from HPV-16, and ST antigen from SV40 [48] (GSE2487 DataSets).
HF1 represent immortal human fibroblast expressing hTERT and an empty
vector, and tHF represent transformed human fibroblast expressing the five
oncogenic hits described above.
Additional file 13: Table S3. Transcriptome datasets. Table shows the
details of each cancer dataset, the number of samples with clinical details,
the expression platform, and associated Pubmed IDs for the GEO datasets.
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